@entity2590 is a neoplastic clonal stem cell disorder characterized clinically by @entity2131 and a tendency to progress to @entity3052 . @entity1141 is the pathologic hallmark. The French-American-British classification served as the gold standard for more than two decades. Under the auspice of the World Health Organization, more than 100 hematopathologists in a 3-year cumulative effort issued the new World Health Organization classification, which recognizes multilineage @entity1141 . @entity417 with @entity7139 is divided into two groups. @entity6130 is reclassified under a separate category. @entity417 with @entity7139 in the transformation group was omitted. Finally, @entity7760 is a new subgroup. In addition to the pathologic classification, various prognostic predictors were formatted into scoring systems. Bone marrow blast percentage, @entity1503 , and cytogenetics are the backbone for those prognostic models. The International Prognostic Scoring System is a product of pooled data from previous scoring systems and a useful tool to predict survival and @entity3052 evolution. This paper discusses the classification and prognosis of @entity2590 and their evolution.

The XXXX : classification and prognosis.

@entity7139 :: ('MESH:D000754', 'Disease') :: ['excess blasts'] @entity417 :: ('MESH:D000740', 'Disease') :: ['Refractory anemia'] @entity7760 :: ('MESH:C535323', 'Disease') :: ['5q-syndrome'] @entity6130 :: ('MESH:D015477', 'Disease') :: ['Chronic myelomonocytic leukemia'] @entity2590 :: ('MESH:D009190', 'Disease') :: ['myelodysplastic syndromes', 'Myelodysplastic syndrome'] @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute myelogenous leukemia'] @entity1503 :: ('MESH:D006402', 'Disease') :: ['cytopenias'] @entity2131 :: ('MESH:C536572', 'Disease') :: ['bone marrow failure'] @entity1141 :: ('MESH:C535662', 'Disease') :: ['dysplasia', 'Dysplasia']
@entity2590 :: (MESH:D009190,Disease) :: ['myelodysplastic syndromes']
